EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The therapeutic potential of an allosteric non‐competitive CXCR1/2 antagonist for diabetic nephropathy

Chiara Grasselli, Silvia Bombelli, Vittoria D'Esposito, Michele Francesco Di Tolla iD, Vincenzo L'Imperio, Francesca Rocchio iD, Martina Sara Miscione, Pietro Formisano, Fabio Pagni, Rubina Novelli, Pier Adelchi Ruffini iD, Andrea Aramini und 3 weitere

Diabetes/Metabolism Research and Reviews · 2023

DOI: 10.1002/dmrr.3694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2023. Verfasst von Chiara Grasselli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Receptors, Interleukin-8B, Receptors, Interleukin-8A, Podocytes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero dello Sviluppo Economico, Ladarixin as new Juvenile Diabetes Inhibitory Agent, Fondo crescita sostenibile-Proposal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Diabetic nephropathy is a major consequence of inflammation developing in type 1 diabetes, with interleukin‐8 (IL‐8)‐CXCR1/2 axis playing a key role in kidney disease progression. In this study, we investigated the therapeutic potential of a CXCR1/2 non‐competitive allosteric antagonist (Ladarixin) in preventing high glucose‐mediated injury in human podocytes and epithelial cells differentiated from renal stem/progenitor cells (RSC) cultured as nephrospheres. Materials and Methods We used human RSCs cultured as nephrospheres through a sphere‐forming functional assay to investigate hyperglycemia‐mediated effects on IL‐8 signalling in human podocytes and tubular epithelial cells.

Results

High glucose impairs RSC self‐renewal, induces an increase in IL‐8 transcript expression and protein secretion and induces DNA damage in RSC‐differentiated podocytes, while exerting no effect on RSC‐differentiated epithelial cells. Accordingly, the supernatant from epithelial cells or podocytes cultured in high glucose was able to differentially activate leucocyte‐mediated secretion of pro‐inflammatory cytokines, suggesting that the crosstalk between immune and non‐immune cells may be involved in disease progression in vivo.

Conclusions

Treatment with Ladarixin during RSC differentiation prevented high glucose‐mediated effects on podocytes and modulated either podocyte or epithelial cell‐dependent leucocyte secretion of pro‐inflammatory cytokines, suggesting CXCR1/2 antagonists as possible pharmacological approaches for the treatment of diabetic nephropathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesReceptors, Interleukin-8BReceptors, Interleukin-8APodocytesHumansCells, CulturedCell DifferentiationInterleukin-8Epithelial CellsStem CellsAllosteric Regulation

Stichwörter der Autor:innen

CXCR1/2IL-8Ladarixindiabetic nephropathyrenal stem celltype 1 diabetes

Substanzen

Receptors, Interleukin-8BReceptors, Interleukin-8ACXCR2 protein, humanInterleukin-8

Autor:innen und Institutionen

  • Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
  • Pathology Department, IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy.
  • Dompé Farmaceutici S.p.A., Naples, Italy.
  • Research and Development, Dompé Farmaceutici S.p.A., Milano, Italy.
  • Dompé Farmaceutici S.p.A., L'Aquila, Italy.

ORCID-Profile: Michele Francesco Di Tolla, Francesca Rocchio, Pier Adelchi Ruffini, Roberto Perego

Förderung

  • Ministero dello Sviluppo Economico
  • Ladarixin as new Juvenile Diabetes Inhibitory Agent
  • Fondo crescita sostenibile-Proposal

Zitieren

APA

Grasselli, C., Bombelli, S., D'Esposito, V., Di Tolla, M. F., L'Imperio, V., Rocchio, F., Miscione, M. S., Formisano, P., Pagni, F., Novelli, R., Ruffini, P. A., Aramini, A., Allegretti, M., Perego, R., & De Filippis, L. (2023). The therapeutic potential of an allosteric non‐competitive CXCR1/2 antagonist for diabetic nephropathy. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3694

Vancouver

Grasselli C, Bombelli S, D'Esposito V, Di Tolla MF, L'Imperio V, Rocchio F, et al. The therapeutic potential of an allosteric non‐competitive CXCR1/2 antagonist for diabetic nephropathy. Diabetes/Metabolism Research and Reviews. 2023. doi:10.1002/dmrr.3694

BibTeX
@article{Grasselli2023,
  author = {Grasselli, Chiara and Bombelli, Silvia and D'Esposito, Vittoria and Di Tolla, Michele Francesco and L'Imperio, Vincenzo and Rocchio, Francesca and Miscione, Martina Sara and Formisano, Pietro and Pagni, Fabio and Novelli, Rubina and Ruffini, Pier Adelchi and Aramini, Andrea and Allegretti, Marcello and Perego, Roberto and De Filippis, Lidia},
  title = {The therapeutic potential of an allosteric non‐competitive CXCR1/2 antagonist for diabetic nephropathy},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2023},
  doi = {10.1002/dmrr.3694}
}
Kostenlos starten →